Drug
Anbenitamab clinical trials
Also written KN026.
- studies test it
- 8
- open now
- 2
- in phase 3
- 3
- first study started
- 2018
Keep track of what changes. Save the anbenitamab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
8 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 3 |
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 4
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 0
Jiangsu Alphamab Biopharmaceuticals Co., Ltd (5) · Shanghai JMT-Bio Inc. (3)
Often tested with
Tested in the same studies.
Docetaxel (2) · Concurrent Chemotherapy (1) · Erfonrilimab (1) · Enlonstobart (1) · Trastuzumab (1) · Pembrolizumab (1)
Studies
Open first, then newest update. How each study uses anbenitamab is read from its arms, and is right about nine times in ten.
Testing it · 8
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerRecruitingPhase 3Shanghai JMT-Bio Inc.NCT07441460Written as KN026
- A Study of KN026-based Combination Therapy in HER2-positive Gastric CancerNot yet recruitingPhase 2/3Shanghai JMT-Bio Inc.NCT07332533Written as KN026
- A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast CancerActive, not recruitingPhase 3Shanghai JMT-Bio Inc.NCT06747338Written as KN026
- KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction CancerCompletedPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT03925974Written as KN026 10 mg/kg QW
- Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric CancerCompletedPhase 1Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT03619681Written as KN026
- Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast CancerActive, not recruitingPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT04165993Written as Concurrent chemotherapy and KN026
- Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast CancerStatus unknownPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT04881929Written as KN026
- KN026 in Patients With HER2 Expressing Breast Cancer and Gastric CancerStatus unknownPhase 1Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT03847168Written as KN026
Given in every arm · 4 — anbenitamab is usual care beside what is tested
- A Clinical Study of SYS6023 Combination Therapy for Advanced Breast CancerRecruitingPhase 2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07597629Written as KN026
- JSKN003 Combined Treatment of HER2-positive Gastric CancerNot yet recruitingPhase 2Shanghai JMT-Bio Inc.NCT06998771Written as KN026
- Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GCRecruitingPhase 2Peking UniversityNCT06023758Written as KN026
- KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary CarcinomaNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT05985707Written as KN026
Codes
What other systems call anbenitamab · ClinicalTrials.gg INT017798
- UNII (FDA) RHS90QRF9EANBENITAMABOne source FDA
- NCI Thesaurus C162577AnbenitamabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | RHS90QRF9E | ANBENITAMAB | One source FDA |
| NCI Thesaurus | C162577 | Anbenitamab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.